| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2020-02-11 | VANGUARD GROUP INC | G1 Therapeutics, Inc. | 2,013,565 | 5.4% | EDGAR |
| SC 13G/A | 2020-02-07 | FMR LLC | G1 Therapeutics, Inc. | 5,637,226 | 15.0% | EDGAR |
| SC 13G/A | 2020-02-05 | BlackRock Inc. | G1 Therapeutics, Inc. | 2,580,359 | 6.9% | EDGAR |
| SC 13G/A | 2020-01-28 | WELLINGTON MANAGEMENT GROUP LLP | G1 Therapeutics, Inc. | 5,168,184 | 13.8% | EDGAR |
| SC 13G/A | 2019-09-13 | Lumira Capital Investment Management Inc. | G1 Therapeutics, Inc. | 1,028,874 | 2.7% | EDGAR |
| SC 13G/A | 2019-02-13 | FMR LLC | G1 Therapeutics, Inc. | 5,577,754 | 15.0% | EDGAR |
| SC 13G/A | 2019-02-13 | Hatteras Venture Partners IV SBIC, LP | G1 Therapeutics, Inc. | 2,517,695 | 6.8% | EDGAR |
| SC 13G | 2019-02-08 | BlackRock Inc. | G1 Therapeutics, Inc. | 1,963,714 | 5.3% | EDGAR |
| SC 13G/A | 2019-01-28 | FRANKLIN RESOURCES INC | G1 Therapeutics, Inc. | 1,234,858 | 3.3% | EDGAR |
| SC 13G | 2019-01-10 | WELLINGTON MANAGEMENT GROUP LLP | G1 Therapeutics, Inc. | 3,769,615 | 10.1% | EDGAR |
| SC 13D | 2018-02-13 | ESHELMAN FREDRIC N | G1 Therapeutics, Inc. | 3,439,151 | 12.1% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | G1 Therapeutics, Inc. | 4,106,644 | 14.5% | EDGAR |
| SC 13G | 2018-02-13 | Lumira Capital Investment Management Inc. | G1 Therapeutics, Inc. | 1,422,776 | 5.0% | EDGAR |
| SC 13G | 2018-02-13 | Hatteras Venture Partners IV SBIC, LP | G1 Therapeutics, Inc. | 3,861,797 | 13.6% | EDGAR |
| SC 13G | 2018-02-08 | ASTRAZENECA PLC | G1 Therapeutics, Inc. | 2,950,630 | 10.4% | EDGAR |
| SC 13G | 2018-02-06 | FRANKLIN RESOURCES INC | G1 Therapeutics, Inc. | 1,535,616 | 5.4% | EDGAR |
| SC 13G | 2017-12-11 | FMR LLC | G1 Therapeutics, Inc. | 4,106,647 | 14.5% | EDGAR |